An evaluation of axatilimab for the treatment of chronic graft-versus-host disease

20260 citationsJournal Article

Authors

Sriram Banigallapati · Middlesex County College

Abstract

Axatilimab has demonstrated safety, tolerability, and efficacy in clinical trials; however, many questions remain unanswered including long-term safety data, efficacy when compared to other cGVHD therapies, risks and benefits of axatilimab in combination, and role in earlier lines of cGVHD treatment.

Topics & Keywords

Hematopoietic Stem Cell Transplantation Renal Transplantation Outcomes and Treatments Mesenchymal stem cell research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Expert Opinion on Biological Therapy

DOI: 10.1080/14712598.2026.2649515

Field-Weighted Citation Impact: 0.00